Digital therapeutics agency Kaia Well being is partnering with Italian pharma agency Chiesi Group to commercialise its power obstructive pulmonary illness (COPD) rehabilitation app in Europe.
The Kaia COPD answer consists of a cellular app and an interface for motivational assist that goals to ship a personalised pulmonary rehabilitation expertise by training, every day coaching periods and stress aid workouts, augmented with human teaching assist and individualised remedy.
The app is CE marked in Europe as a Class 1 medical gadget. It has been investigated in a single pilot trial and is the topic of an ongoing randomised management trial in Europe.
WHY IT MATTERS
COPD is a gigantic price for healthcare techniques in Europe. The British Lung Basis estimates that lung circumstances within the UK price the NHS and sufferers round £9.9 billion annually.
In response to NHS England, respiratory circumstances have an effect on one in 5 folks in England, and are the third greatest reason behind dying. Nevertheless, pulmonary rehabilitation is at the moment solely provided to 13% of eligible COPD sufferers in England.
This partnership claims it is likely one of the first collaborations between a digital therapeutics firm and pharma to assist COPD therapy outcomes by behavioural change, slightly than counting on pharmacology.
THE LARGER CONTEXT
Earlier this yr, Kaia Well being introduced a $28 million Collection B funding spherical led by Optum Ventures, Idinvest and capital300, to drive development of its core digital remedy platforms for musculoskeletal circumstances and to fund its growth into COPD.
In the meantime, Propeller Well being teamed with Novartis in July to co-package its digital well being platform with the pharma large’s bronchial asthma remedy.
AptarPharma just lately acquired Cohero Well being’s digital platform, BreathSmart Related and its corresponding app.
ON THE RECORD
Konstantin Mehl, Kaia Well being founder and president, mentioned: “Our strategic partnership with Chiesi, a rising world firm with a longtime European business presence, brings a wealth of expertise in navigating the respiratory well being panorama in Europe, whereas increasing affected person entry to evidence-based, digital bodily pulmonary rehabilitation.”
Ugo Di Francesco, Chiesi Group CEO, mentioned: “This settlement embodies Chiesi’s dedication to offering the very best stage of care and high quality of life doable for folks residing with COPD and different respiratory ailments, going past merely these points addressable by remedy.”
Stephan Huber, Kaia Well being chief medical officer, mentioned: “Our aim is to supply an answer that’s patient-centric first, digital second. Our COPD answer is a very digitised model of key self-management parts of bodily pulmonary rehabilitation that goals to enhance entry to a confirmed, behavioural COPD intervention in a quickly scalable, patient-focused digital programme.”
Giovanna Amadori, Chiesi Group head of worldwide technique and company growth, mentioned: “Slightly than partnering round a digital intervention which will assist sufferers as a facet profit, our collaboration with Kaia Well being emphasises a patient-focused intervention that makes use of digital to maximise entry for sufferers.”